Early and aggressive treatment of diabetic retinopathy can strongly control the disease and prevent vitreous blood accumulation and retinal neovascularization. Once these complications occur, treatment requires ophthalmic surgery such as vitrectomy, which is often ineffective and can easily cause blindness. Early treatment is mainly medication and laser photocoagulation. The current drug treatment is mainly to control the blood sugar smoothly, reduce fluctuation, and improve the blood status by reducing blood viscosity, lowering blood lipids, and improving retinal microcirculation to improve the oxygen supply and anti-damage ability of the retina. The effects of laser photocoagulation are: ① can close the ruptured and extremely dilated capillaries and microscopic veins to reduce their bleeding; ② by closing the tiny arteries in the obstructed basin to reduce the pressure of obstructed venous return; ③ communicate the connection between the retina and the choroid to facilitate the absorption of bleeding. ④release macular edema to close the retinal non-perfused area. Improve the hypoxic state and inhibit the occurrence of neovascularization; photocoagulation can directly destroy the neovascularization on the retina and promote its atrophy. Diabetic patients need to undergo ophthalmologic confirmation once a year, once for stage 2 early diabetic retinopathy, patients need to be followed up once every 3~6 months, pre-proliferative patients once every 1-2 months; proliferative (DRP) patients need to be followed up once a week.